fashion -WSS

fashion

author：hotspot 2025-08-28 03:35:02 - browse：1

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.

Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

The “Roi” in Roivant stands for “return on investment” and with this deal, the biotech, founded by Republican presidential candidate Vivek Ramaswamy but now run by CEO Matt Gline, certainly delivered. Last December, it essentially acquired RVT-3101 from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： STAT readers on older presidents, polypills, Medicare, and more

focus

WSS

After half a century, Israel moves to evict squatter from his cave home on the beach

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Alabama IVF ruling threatens families facing fatal genetic disease

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

How are insurers handling Leqembi and related scans?

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

knowledge

fashion

knowledge

Psychedelics group wrestles with new pharma identity

Antibody drugs appear effective. Now can we make enough of them?

Supreme Court strikes down use of affirmative action

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Duchenne breakthrough therapy leaves behind pioneering families

R1 RCM gets $5.8 billion buyout offer from private equity firm

Heart attack and stroke risk calculators need revising

The debate over Covid

knowledge

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

He's a Nobel laureate. Critics say he was misleading on Covid

Dario to buy mental health app maker Twill in cash and stock deal

A Greenpeace activist is fined for crash

After half a century, Israel moves to evict squatter from his cave home on the beach

Blinken talks high

hotspot

hotspot

focus

explore